Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma

NCT06984146 is registered in ClinicalTrials.gov with National Medical Research Radiological Centre of the Ministry of Health of Russia as lead sponsor.

NCT NCT06984146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06984146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
Lead sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2025
Completion date
January 31, 2029
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, adult